Although there is currently no specific therapy targeting ERG and its prognostic value is still unclear, there is interest in investigating new therapeutic avenues in the context of ERG-positive tumors as ERG fusion remains one the most frequently altered genes in PCa and its activity is essential for the viability of ERG-positive tumor cells. The gene discussed is ERG; the disease is neoplasm.